Intellia Therapeutics' stock experienced a significant pre-market plunge, dropping 6.02% in early trading.

The sharp decline follows the company's disclosure that it entered into a sale agreement with Jefferies LLC for the offer and sale of up to $400 million of its common stock. Such equity financing arrangements typically raise investor concerns about potential dilution of existing shareholders' stakes.

Market reaction to the capital raise announcement appears to have overshadowed other positive regulatory developments, including the recent removal of a clinical hold on a key gene therapy trial, with dilution fears driving the negative sentiment in pre-market trading.